Bryce D. Carmine
Chairman bei KAZIA THERAPEUTICS LIMITED
Vermögen: 43 716 $ am 30.11.2023
Aktive Positionen von Bryce D. Carmine
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
KAZIA THERAPEUTICS LIMITED | Independent Dir/Board Member | 01.01.2015 | - |
Chairman | 18.01.2024 | - | |
Director/Board Member | 01.01.2015 | 18.01.2024 | |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Chairman | 01.03.2015 | - |
Chief Executive Officer | 01.03.2015 | 13.11.2023 |
Karriereverlauf von Bryce D. Carmine
Ehemalige bekannte Positionen von Bryce D. Carmine
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ELI LILLY AND COMPANY | Director/Board Member | 05.05.2011 | 05.05.2011 |
Corporate Officer/Principal | 22.03.2010 | 01.01.2012 | |
Sales & Marketing | 01.01.1983 | 22.03.2010 | |
Eli Lilly Japan KK
Eli Lilly Japan KK Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Japan KK is a Japanese company that manufactures and trades pharmaceutical products. The private company is based in Kobe, Japan. | President | 01.01.1995 | 01.06.1999 |
Eli Lilly Australia Pty Ltd.
Eli Lilly Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Eli Lilly Australia Pty Ltd. manufactures and supplies pharmaceutical products. It develops medicines for diabetes, cancer, immunology, and pain. The company was founded in 1960 and is headquartered in West Ryde, Australia. | Chairman | 01.01.1995 | 01.01.1995 |
Daewoong-Lilly Pharmaceutical Co. | Corporate Officer/Principal | 01.01.1986 | - |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Director/Board Member | 21.11.2008 | - |
Ausbildung von Bryce D. Carmine
Massey University | Undergraduate Degree |
Statistik
International
Australien | 4 |
Vereinigte Staaten | 3 |
Neuseeland | 2 |
Operativ
Director/Board Member | 3 |
Chairman | 3 |
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 7 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
KAZIA THERAPEUTICS LIMITED | Health Technology |
Private Unternehmen | 5 |
---|---|
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
Eli Lilly Japan KK
Eli Lilly Japan KK Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Japan KK is a Japanese company that manufactures and trades pharmaceutical products. The private company is based in Kobe, Japan. | Health Technology |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Health Technology |
Daewoong-Lilly Pharmaceutical Co. | |
Eli Lilly Australia Pty Ltd.
Eli Lilly Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Eli Lilly Australia Pty Ltd. manufactures and supplies pharmaceutical products. It develops medicines for diabetes, cancer, immunology, and pain. The company was founded in 1960 and is headquartered in West Ryde, Australia. | Health Technology |
- Börse
- Insiders
- Bryce D. Carmine
- Erfahrung